Key Points
- CFO Thomas Catinazzo sold 1,800 shares of Relay Therapeutics on April 9 at $15.00 each for $27,000, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- Catinazzo has executed multiple recent sales (including 17,717 shares on April 7) but still directly owns 213,867 shares worth roughly $3.21 million, a 0.83% reduction in his position.
- Relay’s stock opened at $15 (near its 52‑week high), the company has a market cap of about $2.68 billion, and analysts hold a consensus Moderate Buy rating with an average price target of $18.43 after several recent upward revisions.
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the sale, the chief financial officer directly owned 213,867 shares of the company's stock, valued at approximately $3,208,005. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thomas Catinazzo also recently made the following trade(s):
- On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
- On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total value of $14,322.75.
- On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total value of $105,308.40.
Relay Therapeutics Stock Up 3.4%
Shares of NASDAQ:RLAY opened at $15.00 on Friday. The company has a market cap of $2.68 billion, a P/E ratio of -9.26 and a beta of 1.57. Relay Therapeutics, Inc. has a 52 week low of $2.07 and a 52 week high of $15.00. The business has a fifty day simple moving average of $9.95 and a 200-day simple moving average of $8.11.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.06. The business had revenue of $7.00 million during the quarter, compared to analysts' expectations of $4.34 million. Sell-side analysts expect that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Relay Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of RLAY. Torren Management LLC purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth about $30,000. Smartleaf Asset Management LLC boosted its position in shares of Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company's stock worth $37,000 after buying an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth about $46,000. Captrust Financial Advisors purchased a new stake in shares of Relay Therapeutics in the second quarter worth about $49,000. Finally, Cerity Partners LLC purchased a new stake in shares of Relay Therapeutics in the second quarter worth about $51,000. Hedge funds and other institutional investors own 96.98% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the company. Oppenheimer reaffirmed an "outperform" rating on shares of Relay Therapeutics in a research report on Monday, March 16th. Wells Fargo & Company lifted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, March 17th. Barclays lifted their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday. Guggenheim upped their price target on Relay Therapeutics from $15.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, March 13th. Finally, Citizens Jmp upped their price target on Relay Therapeutics from $15.00 to $17.00 and gave the stock a "market outperform" rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.43.
View Our Latest Report on RLAY
Relay Therapeutics Company Profile
(
Get Free Report)
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
